Aptose Biosciences Inc (APTO)

[dcaf7]

A new redesigned Corporate presentation is available.
https://d1io3yog0oux5.cloudfront.net/_6677d14bd1e90de12add105cb8a9fa10/aptose/db/776/7450/pdf/Aptose+Corporate+Presentation+April+2023.pdf
Some highlights:
1. Slide 7 shows Gilteritinib FY 2022E sales: ~$355M. It is for 2nd+ line patients with Flt3 mutations. Tusp first indication could be monotherapy for 3d+ line.
2. Slide 19 and 20. A new response with 40 mg dose is a CRp. This patient has TP53 mutation. So, now they have two TP53 patients with CR/CRp
3. Slide 23. EOP1 meeting moved to Q2 2023. It is 3d time they are moving the date. Registrational study in the very end of 2023. Not sure whether it is an actual start or protocol submission.
4. Slide 33. Quotes about lack of myelosuppression. I like this one, “…I'll tell you what was most interesting to me when I look at the duration of responses and the way the study was done. There are responses, clearly responses. But here's the thing. The drug did not have to be stopped in order to see a CR or a CRh. Don’t underestimate that. That's really important because it limits our combination partners because of myelosuppression with the FLT3 inhibitors we have.”